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Abstract 
Background. Little is known about normal kidney function level and the 
prognosissignificance of low estimated glomerular filtration rate(eGFR) in the elderly. 
Methods. We determined age and sex distribution of eGFR with both the Modification of 
Diet in Renal Disease (MDRD) study and the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equations in 8705 community-dwelling elderly aged ≥ 65 years and 
studied its relation to 6-year mortality. In a subsample of 1298 examined at 4 yrs, we assessed 
annual eGFR decline and clinically relevant markers including microalbuminuria (3-30 
mg/mmolcreatinine) with diabetes, proteinuria ≥50 mg/mmol, haemoglobin<11 g/L, or 
resistant hypertension despite 3 drugs. 
Results. Median (interquartile range) MDRD eGFR was 78 (68-89)mL/min/1.73m
2 
in men 
and 74 (65-83)in women; there were 79 (68-87) and 77 (67-85) for CKD-EPI eGFR, 
respectively. Prevalence of MDRD eGFR< 60mL/min/1.73m
2 
was13.7%, and of CKD-EPI 
eGFR, 12.9%. After adjustment for several confounders, only those with an eGFR<45 
mL/min/1.73 m
2
 had significantly higher all-cause and cardiovascular mortality than 
thosewith an eGFR of 75 to 89 mL/min/1.73 m
2 
whatever the equation. In subsample men and 
women with MDRD eGFR of 45-59 mL/min/1.73m
2
, 15% and 13% had at least one clinical 
marker, and 15% and 3% had microalbuminuria without diabetes, respectively; these 
percentages were 41% and 21%, and 23% and 10%, in men and women with eGFR<45, 
respectively. Mean MDRD eGFR decline rate was steeper in men than women, 1.75 vs 1.41 
mL/min/1.73m
2
 per year. 
Conclusion.Moderately decreased eGFR is more often associated with clinical markers in 
men than women. In both sexes, eGFR< 45 mL/min/1.73m
2
 is related to poor outcomes. The 
CKD-EPI and the MDRD equations provide very similar prevalence and long-term risk 
estimates in this elderly population. 
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Short summary 
Impaired kidney function is common in the elderly, but its clinical and prognosis 
significancehas been poorly assessed so far. In both sexes, an estimated GFR < 45 
mL/min/1.73m
2
 is related to increased all-cause and cardiovascular mortality. Only a fraction 
of the elderly with moderately impaired function, higher in men than women, have markers of 
kidney damage who might deserve specialist assessment. In addition to proteinuria, resistant 
hypertension and anaemia should be considered to appraise the clinical significance of kidney 
impairment in the elderly. 
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Introduction 
Chronic kidney disease (CKD) as defined by the Kidney Disease Outcome Quality 
Initiative (K/DOQI) is increasingly recognized as a public health priority and targeted in 
prevention programs.[1,2][3] Routine reporting of estimated glomerular filtration rate (eGFR) 
has led to label up to nearly half of the elderly as having CKD [4-7] and increased referrals to 
nephrologists.[8,9] Because CKD diagnosis in many of these subjects is based only on either 
microalbuminuria or moderately decreased eGFR (i.e., 30-59 mL/min/1.73 m
2
),controversy 
exists about its clinical relevance,[10-17] especially given how little is known about normal 
kidney function level [18,19] and the epidemiology of CKD in the elderly.[20,21] 
 More information is needed about the prevalence of clinically significant kidney 
markers such as clinical proteinuria,[22] resistant hypertension,[23] or anaemia[24] in the 
older people.[21,26] Data on eGFR change over time is also needed to better define rapid 
decline in this population.[27-29] Moreover, although several studies have shown increased 
mortality risk with decreasing eGFR,[30-34] others suggest age attenuates these 
associations.[35-39] Finally, use of creatinine enzymatic assay and development of new 
equations improved eGFR assessment, but while the CKD Epidemiology Collaboration 
(CKD-EPI)[40] equation has shown to better categorized middle-aged individuals with 
respect to long-term outcomes compared with the Modification of Diet in Renal Disease 
(MDRD) Study equation, [41] distribution of eGFR values according to one another and risk 
implications in the oldest are unknown. [42] 
 We therefore determined age- and sex-specificeGFR using both the MDRD and CKD-
EPI equations in community-dwelling people aged 65 years and older participating in the 
Three-City (3C) cohort study and studied their relations to 6-year all-cause and cardiovascular 
mortality risks. In a subsample, we also assessed eGFR decline at 4 years and CKD markers.
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Subjects and Methods 
 
Study design and participants 
The 3C study is a community-based, prospective cohort that included non-institutionalized 
individuals aged 65 years or older randomly selected from the electoral rolls of Bordeaux, 
Dijon, and Montpellier (France) from March 1999 through March 2001. The acceptance rate 
of 37% yielded a sample of 9294 participants. Details of the study design are reported 
elsewhere.[43] Here, we studied 8705 participants with baseline serum creatinine and 
mortality data for 6 years; a subsample of 1298 from Bordeauxwas also seen at four years, to 
assess eGFR decline and CKD markers (Figure 1). 
Information 
Baseline data came from face-to-face interviews and physical examination. Cardiovascular 
diseases and cardiorenal risk factors were recorded in detail. Open questions about surgery, 
hospitalization, treatment, and 100% health insurance benefits for severe illness in the last 2 
years provided a history of kidney diseases and nephrectomy. At both baseline and 4 years, 
medication use was recorded and coded according to the WHO’s Anatomical Therapeutical 
Chemical classification;[44] height and weight were measured and body mass index (BMI) 
was calculated; seated blood pressure (BP) was measured twice after 5 minutes rest and 
averaged. Hypertension was defined by a mean systolic BP ≥140 or diastolic BP ≥90 mm 
Hg,[45] or by the use of antihypertensive drugs. Resistant hypertension was defined as a mean 
systolic BP ≥ 140 or diastolic BP ≥ 90 mm Hg despite the use of at least three 
antihypertensive drugs for all participants except those with diabetes or CKD as defined 
below; thresholds for them were ≥130 or 80 mm Hg.[23]. Diabetes was either self-reported or 
defined as fasting glucose ≥ 7 mmol/L or non-fasting ≥ 11 mmol/L (in 1% of the participants) 
or antidiabetic drug treatment. Fasting plasma cholesterol was also measured. 
6 
 
Assessment of kidney function and CKD markers  
Serum creatinine was measured with the Jaffe method in a single laboratory at baseline and in 
a different one at 4 years. In order to standardize creatinine values, 1720 frozen serum 
samples at baseline and 325 at 4 years wereremeasured in a single laboratory with an isotope 
dilution mass spectrometry (IDMS) traceable enzymatic assay previously shown to provide 
very reliable eGFR compared to measured GFR.[25] We then developed equations relating 
the Jaffe and IDMS traceable creatinine and standardized all baseline (1) and follow-up (2) 
values as follows: (1)ScrIDMS= 0.86 x ScrJaffe + 4.40; (2) ScrIDMS= 0.87 x ScrJaffe + 7.85. 
We calculated eGFR in mL/min/1.73 m
2
 with both the MDRD and the CKD-EPI equations 
without correction for ethnicity (which was unavailable).[40,41] At the 4-year follow-up, 
blood and urine were collected in 1298 participants and analyzed for haemoglobin (Hb), 
urinary protein:creatinine ratio (PCR), and albumin:creatinine ratio (ACR) when proteinuria 
was < 300 mg/L. Dipstick haematuria and leukocyturia were recorded. Anaemia was defined 
as Hb< 11 g/dL.[24] Clinical proteinuria was defined as a PCR> 50 mg/mmol and 
microalbuminuria as an ACR of 3-30 mg/mmol. These data were missing for 40 participants. 
In the sub-sample, we used the UK National Institute for Health and Clinical Excellence 
(NICE)[22] and 2009 KDIGO Controversies Conference [46] recommended modifications to 
define CKD stages and the mean of baseline and 4-year eGFR values to classify individuals. 
CKD stage 1-2 was defined as a mean eGFR ≥ 60 mL/min/1.73 m2 with ACR≥ 3 mg/mmolor 
clinical proteinuria; stage 3A, as an eGFR of 45-59, and 3B or higher, as eGFR< 45.  
Mortality 
Six-year mortality was assessed by active follow-up of all participants. It remained unknown 
for only 8 participants. Causes of deathwereascertained by an adjudication committeeusing all 
availablemedical data fromhospitals, familyphysicians or specialists, and proxy interviews as 
reportedearlier[Ref] 
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Statistical analysis  
We compared baseline characteristics between the participants with and without 
(n=589)creatinine values, with and without the 4-year follow-up, and with and without CKD 
risk factors - obesity, BP ≥ 160/100, diabetes, history of cardiovascular disease - or self-
reportedkidney disease. Subjects without creatinine values were older than those with (76.6 
versus 74.2 years), had significantly more cardiovascular diseases, but did not differ for other 
CKD risk factors after adjustment for age (data not shown). We calculated mean, 
median,interquartile range, and 5
th
 percentile for both MDRD and CKD-EPI eGFR, by sex 
and 5-year age group, in all participants, and in those with and without CKD or risk factors. 
Distribution by eGFR stratum was compared between the two equations. We also provided 
these values for serum creatinine. Adjusted all-cause and cardiovascular mortality hazard 
ratios (HR) associated with MDRD- and CKD-EPI- eGFR per 15 mL/min/1.73 m
2
 stratum 
were then estimated in the overall population and by sex with Cox models and eGFR of 75 to 
89 as the reference category. The 8 participants who were lost to follow-up were excluded. 
Proportional hazard assumption was checked by examining Cox model residuals. An annual 
eGFR slope in mL/min/1.73 m
2
/year was calculated for each participant as the difference 
between baseline and 4-year values divided by exact follow-up time. We used a general linear 
model to estimate adjusted eGFR slopes (SAS GLM procedure, lsmeans statement with 
obsmargins option) and 95% confidence intervals, by sex, age, hypertension and diabetes 
status, and mean eGFRvalues. The percentages of participants with eGFR decline rate 
>4ml/min/1.73m
2
 are alsoshownaccording to thesefactors. [Ref 3]Finally, we studied the 
prevalence of each kidney markers according to meanMDRD-eGFR at 4 years. We also 
evaluated the prevalence of CKD stages at 4 yrs by sex and diabetes status, as well as the 
distribution of at least one clinical marker (among microalbuminuria associated with diabetes, 
clinical proteinuria, resistant hypertension or anemia), isolated microalbuminuria, and low 
8 
 
eGFR alone, by CKD stage. Statistical analyses were performed with SAS 9.2 (SAS Institute, 
Cary, NC) and R 2.8.1 (R Development Core Team, 2009). 
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Results 
Baseline characteristics  
More than 80% of the participants had at least one CKD risk factor, but fewer than 1% 
reported kidney disease (Table 1). They were older, more often men, and had lower eGFR 
with either equation than their counterparts without CKD risk factors or kidney disease (all p-
values <0.0001). Baseline eGFRs and BMI were higher in participants with than without the 
4-year follow-up (p<0.001); they were also more often women and had less stage 2 
hypertension (p<0.05), but other characteristics were similar.  
 
Age- and sex-specific serum creatinine and eGFR values  
MDRD eGFRs ranged from 17 to 176 mL/min/1.73 m
2
 and CKD-EPI eGFRs from 16 to 109, 
for serum creatinine values from 32 to 322 µmol/L (Table 2 and Supp Table). Gradient for 
age was steeper with the CKD-EPI than the MDRD equation. Mean eGFR was higher in men 
than women using either equation, but differences between sexes were attenuated with the 
CKD-EPI equation. All eGFR values were lower in participants with than without CKD risk 
factors. The CKD-EPI equation reclassified 117 participants (9.8%) with MDRD eGFR< 60 
mL/min/1.73 m
2
 upward to an eGFR ≥ 60 and 49 (<1%) with MDRD eGFR ≥60 downward to 
an eGFR<60; 49.3% of those with MDRD eGFR ≥ 90 were reclassified downward(Table 3). 
 
Hazard ratios for 6-year mortality related to baseline eGFR 
After adjustment for several confounders, only those with an eGFR<45 mL/min/1.73m
2
had 
significantly higher all-cause mortality than those with an eGFR of 75 to 89, in both men and 
women and with either equation. (Table 3) Cardiovascular mortality significantly exceeded 
that of the reference group foreGFRs<60 mL/min/1.73 m
2
 in the overall population, but for 
each sex taken separately, it significantly exceeded only for eGFR<45 mL/min/1.73 m
2
. 
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Estimated GFR decline according to participant baseline characteristics and mean eGFR 
In the 1298 participants with a 4-year follow-up, the MDRD eGFR decreased in nearly four 
out of ten by > 2 mL/min/1.73 m
2
/yr, one out of six by > 4, and in 10% by > 5 mL/min/1.73 
m
2
/yr. The adjusted mean annual decline was significantly steeper in men than women and in 
those with than without diabetes at baseline, but was not related to age and individual mean 
MDRD eGFR. There was a nonsignificant trend towards steeper decline with increasing 
blood pressure in those with hypertension. Mean CKD-EPI eGFR decline was 1.53±2.35 
mL/min/1.73 m
2
/yr, and was similarly related with studied factors (data not shown). 
 
Prevalence of kidney damage markers according to mean MDRD eGFR level  
In the sub sample, as MDRD eGFR decreased from ≥75 to <45 mL/min/1.73 m2, the 
prevalence of microalbuminuria increased from 7.4% to 25.6%, that of microalbuminuria 
associated with diabetes from 2.8% to 9.8%, clinical proteinuria from 0.6% to 14.0%, 
resistant hypertension from 3.3% to 15.7%, and of anaemia from 1.5% to 7.5% (Figure 2). 
Haematuria without leukocyturia did not increase with decreasing MDRD eGFR. 
 
Prevalence of CKD stages and percentage of kidney damage markers by stage  
In the sub sample,the prevalence of CKD using MDRD eGFR was 27.9%; it was 7.0% for 
stages 1-2, 16.7% for 3A, and 4.2% for 3B or higher. (Figure 3) More men than women had 
CKD stages 1-2, but more women than men had stage 3. Nearly half of both men and women 
at stages 1-2 had at least one clinically relevant marker and the other half microalbuminuria 
alone. In men and women with stage 3A, 30% and 16% had markers of kidney damage, and 
with stage 3B or higher, 64% and 31%, respectively. The prevalence of CKD stages 1-2 was 
three times higher in those with than without diabetes, 15.7% vs 5.7%;it was closer for other 
stages: 15.1 vs 16.9% for stage 3A, and 5.7% vs 3.9% for stage 3B or higher. Using CKD-
EPI, the overall prevalence was also 27.9%; it was 7.2% for stages 1-2, 15.4% for 3A, and 
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5.3% for 3B or higher. 
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Discussion 
 Knowledge of the specific aspects of CKD epidemiology in the elderly is essential to 
implement appropriate management. The determination of eGFR distribution for old and very 
old people, based on IDMS traceable serum creatinine and appropriate equations, is thus an 
important step forward. This study showed that impaired kidney function was associated with 
excess mortality with very similar risk estimates using the MDRD or the CKD-EPI equations. 
Moreover, more than one out of six individuals in this population had fast eGFR decline rate, 
> 4 mL/min/1.73 m2. The most original findings indicate that only a fraction of those with 
decreased eGFR have markers of kidney damage and that others than proteinuria should be 
considered to assess its clinical significance in the elderly.  
 The large sample size of this population and the low number of participants lost to 
follow-up (8 out of 8,705 at six years) are major strengths of this study. Other strengths 
include the use of standardized measures of creatinine over 4 years which reduced systematic 
bias in the estimate of eGFR decline.  This study also has limitations. First, the participation 
rate was low, and those who participated differedsomewhat in age and sex distribution as 
comparedwith the general population aged 65 years and over in the threetowns.[43]Moreover, 
the recruitmentprocedureled to the selection of urban participants only, whoalsohada higher 
socioeconomic levels than the overall French population. Although this might have led to 
underestimate CKD prevalence, it should not have biased the relations between eGFRlevel 
and the studied markers and outcomes. Second, data on ethnicity were not available to 
calculate eGFR. Because elderly people selected from these cities' electoral rolls are unlikely 
to be of African origin, this factor should have minimal impact on eGFR estimates, but our 
reference values are only generalizable to European or North African elderly. Third, baseline 
data on ACR/PCR would have been valuable to assess the independent impact on decline and 
mortality and to assessrisk stratification usingeGFR and ACR. Fourth, 26% of Bordeaux 
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participants alive at 4 years declined the follow-up study. They differ slightly from those 
included with respect to age and sex, but were highly comparable for the other baseline data 
including eGFR. This may have decreased study power, particularly in the subgroup 
analyses,but is unlikely to have systematically biased our estimates of eGFR decline. In 
contrast, the 137 participants who died within 4 years are likely to be those with more rapid 
decline,[29] and this may have underestimated the observed rate. Finally, eGFR decline rate 
was assessed based on only two creatinine measurements which may have reduced the 
accuracy of estimates, but other sources of inaccuracy were well controlled: creatinine 
measurements were standardized over the study period, and adjustment for individual mean 
eGFR should have reduced regression to the mean.[47,48] 
 It is well established that kidney function decreases with age, but the magnitude of 
normal decline, measured by a reference method, is unknown in the oldest groups. Our age- 
and sex-specific mean MDRD eGFR values in participants without CKD risk factors were 7-
12 mL/min/1.73 m
2
 higher than those provided in 869 Dutch subjects aged 65 years or older, 
free from kidney or cardiovascular disease, hypertension, and diabetes.[18]This is likely to be 
due to the use of non IDMS traceable creatinine and early MDRD equation in the Dutch 
study,[18] which underestimates true GFR at higher levels.[40] Another likely explanation 
may be a healthier profile in the 3C population. As expected, eGFR values with either 
equation were lower in those with than without CKD risk factors, and differences tended to 
widen with age and in men compared with women. In contrast with what was observed in the 
middle-aged population of the Atherosclerosis Risk in Communities (ARIC) study, the CKD-
EPI equation reclassified upward less than 10% of the 3C participants with MDRD eGFR less 
than 60 mL/min/1.73 m
2
versus about 45% in ARIC participants,[42]  resulting in little impact 
on the prevalence of CKD stage 3 or higher, 12.9 vs 13.7%. On the opposite side, while only 
those with MDRD eGFR> 120 mL/min/1.73 m
2
 were reclassified downward with the CKD-
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EPI equation in the ARIC study, this was observed in nearly 50% of the 3C participants with 
MDRD eGFR> 90, resulting in lesser discrimination in the upper range of eGFR values. As 
previously noticed from the properties of the CKD-EPI equation compared with the MDRD 
equation, the gradient with age was steeper, and differences between men and women at each 
age were smaller.[40] 
 Few population-based studies have investigated eGFR changes over time.[27-29] Our 
annual rates of eGFR decline, 1.46 mL/min/1.73 m
2 
per year with the MDRD equation and 
1.53 with CKD-EPI, compared with the 1.49 mL/min per year based on creatinine clearance 
in the 70-79 year-olds from The Longitudinal Aging Study,[27] but was greater than in the 
Cardiovascular Health Study (CHS) elderly population, 0.4 mL/min/1.73 m
2
 per year.[29] 
Differences in creatinine assays and eGFR equations between studies probably explain this 
discrepancy. As in another community-dwelling elderly cohort,[28]eGFR declined faster in 
men than women, in those with than without diabetes, but no trend appeared as individual 
mean eGFR decreased. Although there was a trend toward steeper decline in those with 
poorer BP control, the association was nonsignificant in this population. The K/DOQI [3] 
defines decline rates higher than 4 mL/min/1.73 m
2
 per year as “fast”, as individuals with 
eGFR<60 mL/min/1.73 m
2
 might reach end-stage kidney disease within 10 years. This was 
found in 17% of the 3C participants. In contrast, the UK NICE defines progression as a 
decline >5 mL/min/1.73 m
2
 within one year or >10 mL/min/1.73 m
2
 within 5 years.[22] More 
than a third of 3C participants had an annual decline  >2 mL/min/1.73 m
2
, i.e., 10 in 5 years, 
but 9.9% > 5 mL/min/1.73 m
2
, which is slightly higher than the 6.8% observed in the UK East 
Kent population aged 70 to 80 years old.[51] Although it is well-known that mortality risk 
outweighs that of end-stage kidney disease,[35,36,52] this percentage may more closely 
assess the fraction of the elderly population with significant CKD progression to be targeted 
for management. 
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 Several studies have shown that the mortality risk associated with a given eGFR level 
is attenuated in the elderly.[14,34,38,39,53] In younger individuals, mortality risk exceeds 
that of their reference category at an eGFR of 60 mL/min/1.73 m
2
,
21
 but in those older than 
75, the relevant eGFR would be closer to 45 mL/min/1.73 m
2
.
23 
[38] Our results are consistent 
with these studies when using the MDRD equation to estimate GFR. Using the CKD-EPI 
equation provided very similar hazard ratio estimates, but in women, that for cardiovascular 
mortality in those with an eGFR of 45 to 60 mL/min/1.73 m
2 
was of borderline significance. 
 This study assessed the severity of kidney damage, based on current recommended 
criteria for specialist referral and available evidence that treatment can improve patient 
outcomes.[3,22-24] As previously observed,[5]microalbuminuria was common, but was 
associated with diabetes in only one third of cases. Although microalbuminuria is a well-
established risk factor of both end-stage kidney disease and death,[37,39,54,55] only in this 
latter case is it targeted by therapeutic guidelines.[3,22,56,57] In contrast, clinical proteinuria, 
a modifiable risk factor for CKD progression,[22] was uncommon above an eGFR of 45 
mL/min/1.73 m
2
, which is consistent with findings for older adults in the US.[57] Another 
sign of disease severity requiring specialist referral is resistant hypertension, defined by the 
2004 K/DOQI as poor BP control despite the use of at least three antihypertensive 
drugs.[23,58] Whereas several studies have shown a high prevalence of uncontrolled BP 
among those with CKD,[59-61] that of resistant hypertension has not been specifically 
assessed. Here, it affected 6% of those at CKD stage 3A and 16%, at stage 3B or higher. 
K/DOQI defined anaemia[24] is also an early and severe CKD complication.[25,26] Though 
less common than resistant hypertension, anaemia may help identify elderly people with true, 
but poorly proteinuric CKD. Finally, disproportionately high rates of CKD stage 3 as 
compared with stages 1-2 were often observed in the elderly, e.g., 38% vs 10% in NHANES,
3
 
an odd finding which nourished the controversies about its clinical significance.[57] Although 
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such disproportion was not seen in the 3C study with either equation, it is clear that kidney 
markers together with eGFR level provided a more relevant distribution for disease severity 
stages than previoulsy observed in the older population. 
 In conclusion, we have shown that the CKD-EPI equation may not improve 
categorization of elderly people with respect to CKD and long-term mortality risk compared 
with the MDRD equation. Only a fraction of those with impaired function, higher in men than 
women, have markers of kidney damagewho might deserve specialist assessment and 
appropriate care.This study provides evidence that markers other than proteinuriaare needed 
to distinguish aging kidneys from true CKD and avoid unnecessary referrals in the elderly 
with moderately decreased eGFR, particularly in women.[62-64] 
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Table 1. Baseline characteristics of the Three-City study participants.  
 
 
Overall 
(8,705) 
CKD risk factors or known 
kidney disease 
Subsample 
with 4-year 
follow-up 
(1,298) 
(N) 
No 
(3,768) 
Yes 
(4,937) 
Age in years 
Women 
Income (€/month) 
<760 
760-1499 
1499-2299 
>2300 
no response 
School education < 9 years 
74.3 ± 5.5 
60.5 
 
5.3 
28.8 
26.8 
33.1 
6.0 
63.1 
73.3±5.2 
67.8 
 
4.7 
27.5 
27.1 
34.5 
6.1 
60.8 
75.1±5.7 
54.9 
 
5.7 
29.7 
26.5 
32.1 
6.0 
64.7 
74.3 ± 4.9 
63.5 
 
8.2 
35.0 
23.0 
28.2 
5.6 
60.2 
Smoking  
No 
Yes, past 
Yes, present 
 
61.2 
33.2 
5.6 
 
65.6 
28.0 
6.4 
 
57.8 
37.3 
4.9 
 
64.8 
29.8 
5.3 
Hypercholesterolemia 
No  
Yes,≥6.2 mmol/L not treated 
Yes, treated 
 
43.4 
26.5 
30.1 
 
43.8 
30.5 
25.8 
 
43.1 
23.5 
33.4 
 
42.4 
26.1 
31.4 
Diabetes† 
Hypertension ‡ 
Blood pressure ≥ 160/100 
Body mass index > 30 kg/m
2 
History of cardiovascular disease 
9.7 
77.3 
26.3 
13.2 
29.6 
- 
61.3 
- 
- 
- 
17.1 
89.6 
46.4 
23.3 
52.1 
9.7 
77.8 
23.7 
17.4 
29.0 
Known kidney disease 
0.7 - 1.3 
0.7 
 
Use of reninangiotensin system inhibitor 22.9 
 
13.9 
 
29.7 
 
22.6 
 
Serum creatinine (micromol/L) 76.4±18.2 73.6±14.4 78.5±20.4 73.8 ± 17.3 
MDRD eGFR in mL/min/1.73m² 76.0±15.6 76.9±14.5 75.2±16.4 78.3±16.3 
≥ 90 
60-89 
30-59 
<30 
16.7 
69.6 
13.4 
0.3 
16.9 
73.2 
9.8 
0.1 
16.6 
66.8 
16.2 
0.4 
20.7 
67.6 
11.4 
0.2 
CKDEPI eGFR in mL/min/1.73m² 75.4±13.2 76.9±11.9 74.3±14.0 77.2±12.9 
≥ 90 
60-89 
30-59 
<30 
10.2 
76.9 
12.6 
0.3 
11.4 
79.9 
8.6 
0.1 
9.3 
74.6 
15.6 
0.5 
12.9 
76.9 
9.9 
0.4 
Values are means ± sd or percent. 
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate 
†Diabetes was either self-reported or defined as fasting glycemia ≥ 7 mmol/L or nonfastingglycemia ≥ 11 mmol/L  
orantidiabetic drug treatment.  
‡Hypertension defined as blood pressure ≥140/90 mm Hg or antihypertensive drug treatment (stage 2 defined as blood 
pressure ≥ 160 /100 mm Hg with or without antihypertensive drug treatment) [45] 
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Table 2. Age- and sex-specific eGFR values in ml/min/1.73m² calculated with the MDRD and CKD-EPI equations in all participants, and by sub-group 
  All 3C participants 
 Participants without CKD risk factors* 
or known kidney disease 
 Participants with CKD risk factors* 
or known kidney disease 
 Age N Mean ± Std Median (Min-Max) P5 Q1-Q3  N Mean ± Std Median (Min-Max) P5 Q1-Q3  N Mean ± Std Median (Min-Max) P5 Q1-Q3 
eGFR MDRD 
All 65 – 69 2277 79±15 78 (17-168) 58 69-88  1217 79±14 78 (30-168) 58 69-87  1060 79±15 78 (17-132) 57 70-89 
 70 – 74 2808 77±15 77 (25-176) 53 68-86  1248 78±14 77 (30-154) 56 69-86  1560 77±16 77 (25-176) 51 68-86 
 75 – 79 2307 74±15 73 (20-135) 51 64-84  902 75±14 74 (30-132) 53 65-84  1405 74±16 73 (20-135) 49 63-84 
 80 – 84 884 71±17 71 (18-130) 45 61-82  287 74±16 73 (28-120) 51 63-83  597 70±17 69 (18-130) 43 59-82 
 85 – 89 356 68±17 68 (18-121) 40 57-80  97 72±16 71 (37-121) 46 59-82  259 67±17 67 (18-116) 37 56-77 
 ≥ 90 73 65±16 66 (26-101) 40 51-76  17 69±14 69 (44-97) 44 60-78  56 64±17 63 (26-101) 39 51-75 
 all 8705 76±16 75 (17-176) 51 66-85  3768 77±15 76 (28-168) 54 67-85  4937 75±16 75 (17-176) 49 65-85 
                      
Men 65 – 69 900 83±15 81 (17-137) 60 73-92  399 84±15 82 (44-137) 62 73-93  501 82±16 81 (17-130) 59 72-90 
 70 – 74 1170 80±16 80 (28-154) 53 70-89  416 82±15 81 (45-154) 61 71-89  754 79±16 80 (28-129) 51 69-89 
 75 – 79 857 76±17 75 (20-135) 50 65-87  269 77±15 77 (37-132) 55 68-86  588 75±17 74 (20-135) 48 63-87 
 80 – 84 339 75±18 75 (19-130) 46 62-87  90 79±17 78 (35-120) 50 68-88  249 73±18 73 (19-130) 43 60-87 
 85 – 89 152 70±18 69 (18-116) 41 59-81  34 74±15 72 (48-112) 51 63-82  118 69±19 68 (18-116) 35 57-81 
 ≥ 90 23 64±15 63 (41-101) 43 51-73  4 64±5 64 (59-69) 59 60-69  19 64±16 63 (41-101) 41 51-74 
 all 3441 78±17 78 (17-154) 51 68-89  1212 81±15 80 (35-154) 57 71-90  2229 77±17 77 (17-135) 49 67-88 
                      
Women 65 – 69 1377 77±14 76 (30-168) 57 68-85  818 76±13 75 (30-168) 57 68-84  559 77±15 76 (31-132) 55 67-87 
 70 – 74 1638 76±14 75 (25-176) 53 67-84  832 76±14 75 (30-125) 54 67-83  806 76±15 76 (25-176) 52 67-84 
 75 – 79 1450 73±14 72 (26-133) 51 64-82  633 74±14 73 (30-123) 53 64-82  817 73±15 72 (26-133) 49 63-82 
 80 – 84 545 70±16 68 (18-122) 44 59-79  197 71±15 71 (28-117) 51 62-81  348 68±16 67 (18-122) 43 58-78 
 85 – 89 204 67±17 67 (27-121) 40 56-79  63 71±17 69 (37-121) 44 57-83  141 66±16 66 (27-106) 38 55-76 
 ≥ 90 50 66±17 68 (26-97) 39 51-78  13 71±16 72 (44-97) 44 66-78  37 64±18 64 (26-95) 39 50-76 
 all 5264 74±15 74 (18-176) 51 65-83  2556 75±14 74 (28-168) 53 66-83  2708 74±16 73 (18-176) 48 64-83 
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  All 3C participants 
 Participants without CKD risk factors* 
or known kidney disease 
 Participants with CKD risk factors* 
or known kidney disease 
 Age N Mean ± Std Median (Min-Max) P5 Q1-Q3  N Mean ± Std Median (Min-Max) P5 Q1-Q3  N Mean ± Std Median (Min-Max) P5 Q1-Q3 
CKD-EPI eGFR 
All 65 – 69 2277 80±12 82 (16-109) 60 73-90  1217 81±11 82 (31-109) 61 73-90  1060 80±12 82 (16-101) 59 73-90 
 70 – 74 2808 77±12 80 (25-106) 54 70-87  1248 78±11 80 (30-106) 57 71-87  1560 77±13 80 (25-106) 52 70-87 
 75 – 79 2307 73±12 74 (19-99) 50 65-84  902 74±11 75 (30-97) 53 66-84  1405 72±13 74 (19-99) 48 64-84 
 80 – 84 884 69±14 70 (16-93) 44 60-81  287 71±13 73 (27-92) 49 62-81  597 67±14 69 (16-93) 41 58-80 
 85 – 89 356 64±14 66 (16-89) 38 55-77  97 67±13 68 (35-89) 44 58-79  259 63±15 64 (16-88) 35 53-76 
 ≥ 90 73 60±14 62 (24-80) 37 49-73  17 64±11 65 (41-78) 41 56-75  56 59±15 59 (24-80) 36 47-73 
 all 8705 75±13 78 (16-109) 51 67-86  3768 77±12 79 (27-109) 55 69-86  4937 74±14 77 (16-106) 47 66-85 
                      
Men 65 – 69 900 82±11 85 (16-106) 61 75-90  399 83±11 86 (45-106) 63 76-91  501 81±12 84 (16-101) 60 75-90 
 70 – 74 1170 78±12 82 (27-106) 53 71-87  416 80±11 83 (45-106) 61 72-87  754 77±13 81 (27-100) 51 70-87 
 75 – 79 857 73±13 75 (19-99) 49 64-84  269 74±12 76 (35-97) 54 67-84  588 72±14 74 (19-99) 47 63-84 
 80 – 84 339 70±14 73 (18-93) 44 60-82  90 73±12 76 (33-92) 48 66-83  249 69±15 71 (18-93) 41 58-81 
 85 – 89 152 65±14 66 (16-88) 38 56-77  34 68±11 68 (45-87) 47 59-78  118 64±15 65 (16-88) 32 54-77 
 ≥ 90 23 58±12 59 (36-80) 39 47-69  4 60±5 60 (55-65) 55 55-64  19 58±14 59 (36-80) 36 47-70 
 all 3441 76±14 79 (16-106) 50 68-87  1212 79±12 81 (33-106) 56 71-87  2229 75±14 78 (16-101) 47 67-86 
                      
Women 65 – 69 1377 80±11 81 (31-109) 59 72-90  818 79±11 81 (31-109) 60 72-89  559 80±12 81 (32-101) 58 71-90 
 70 – 74 1638 77±12 79 (25-106) 55 70-87  832 77±11 79 (30-98) 56 70-87  806 77±12 79 (25-106) 54 70-87 
 75 – 79 1450 73±12 74 (25-97) 51 65-83  633 73±11 75 (30-94) 53 65-83  817 73±13 74 (25-97) 49 64-84 
 80 – 84 545 68±14 68 (16-92) 44 59-79  197 70±13 72 (27-91) 50 61-81  348 67±14 67 (16-92) 43 58-79 
 85 – 89 204 64±14 65 (25-89) 38 55-77  63 67±14 68 (35-89) 43 55-79  141 63±14 64 (25-84) 35 53-75 
 ≥ 90 50 61±15 65 (24-80) 37 49-75  13 65±12 69 (41-78) 41 62-75  37 60±16 61 (24-80) 36 47-74 
 all 5264 75±13 77 (16-109) 51 67-85  2556 76±12 77 (27-109) 54 68-86  2708 74±14 76 (16-106) 48 65-85 
eGFR: glomerular filtration rate estimated with the MDRD, Modification of Diet in Renal Disease Study, andthe CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration equations ; 
P5, Q1-Q3, are the 5thpercentile and interquartile range of the eGFR distribution 
* Obesity, blood pressure ≥160/100, diabetes, cardiovascular history  
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Table 3. Number of participants (%) reclassified into upper or lower eGFR categories using CKD-EPI- versus 
MDRD study equation. 
 
 
 
CKD-EPI eGFR (mL/min/1.73m²)  
 
<30 30 - 44 45-59 60-89 >90 Total  
MDRD eGFR 
(mL/min/1.73m²) 
<30 
25 0 0 0 0 25 
(0.3) 0 0 0 0  
30-44 
5 171 6 0 0 182 
(0.1) (2.0) (0.1) 0 0  
45-59 
0 18 849 117 0 984 
0 (0.2) (9.8) (1.3) 0  
60-89 
0 0 49 5,914 93 6,056 
0 0 (0.6) (67.9) (1.1)  
>90 
0 0 0 663 795 1,458 
0 0 0 (7.6) (9.1)  
 
Total 30 189 904 6,694 888 8,705 
Note:  In theupper diagonal, eGFR CKD-EPI underestimates eGFR compared to MDRD study equation whereas it overestimates into the 
lower diagonal 
Abbreviations: eGFR, estimated glomerular filtration rate with the CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration and  the 
MDRD, Modification of Diet in Renal Disease study equations
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Table 4. Adjusted hazard ratios for 6-year all-cause and cardiovascular mortality related to baselineeGFR 
using either the MDRD or CKD-EPI equation, overall and by sex. 
 eGFR in ml/min/1.73m² 
 ≥90 75-89 60-74 45-59 30-44 <30 
All participants      
MDRD 1458 3018 3032 982 182 25 
CKD EPI 888 4075 2612 903 189 30 
All-cause mortality      
MDRD 1.1(0.9-1.4) 1(ref) 1.0(0.8-1.2) 1.1(0.9-1.4) 2.2(1.6-3.0) 3.4(2.0-5.9) 
CKD EPI 1.2(0.9-1.6) 1(ref) 0.9(0.8-1.1) 1.1(0.9-1.3) 2.0(1.5-2.7) 3.3(2.0-5.5) 
Cardiovascular mortality      
MDRD 1.4(0.9-2.1) 1(ref) 1.0(0.7-1.4) 1.7(1.1-2.5) 3.7(2.2-6.2) 3.5(1.2-10.0) 
CKD EPI 1.5(0.9-2.6) 1(ref) 0.9(0.6-1.3) 1.6(1.1-2.3) 3.1(1.8-5.0) 4.3(1.8-10.2) 
No of men       
MDRD 773 1240 1008 337 64 14 
CKD EPI 417 1664 918 350 70 17 
All-cause mortality      
MDRD 1.1(0.9-1.5) 1(ref) 1.0(0.8-1.3) 1.1(0.8-1.5) 2.5(1.6-3.8) 2.5(1.2-5.5) 
CKD EPI 1.3(0.9-1.8) 1(ref) 0.9(0.7-1.1) 1.1(0.8-1.4) 2.0(1.3-3.1) 2.9(1.5-5.5) 
Cardiovascular mortality      
MDRD 1.5(0.9-2.4) 1(ref) 1.2(0.7-1.9) 1.6(0.9-2.7) 5.2(2.6-10.3) 1.3(0.2-10.0) 
CKD EPI 1.5(0.8-2.7) 1(ref) 0.9(0.6-1.4) 1.4(0.9-2.3) 3.4(1.7-6.8) 3.1(0.9-10.2) 
No of women       
MDRD 685 1778 2024 645 118 11 
CKD EPI 471 2411 1694 553 119 13 
All-cause mortality      
MDRD 1.2(0.8-1.7) 1(ref) 1.0(0.8-1.3) 1.2(0.9-1.7) 2.1(1.3-3.2) 6.8(3.1-15.0) 
CKD EPI 0.9(0.5-1.5) 1(ref) 1.0(0.8-1.3) 1.1(0.8-1.5) 2.0(1.3-3.0) 4.9(2.2-10.8) 
Cardiovascular mortality      
MDRD 1.1(0.5-2.3) 1(ref) 0.7(0.4-1.3) 1.7(0.9-3.0) 2.5(1.1-5.5) 8.6(2.4-31.0) 
CKD EPI 1.3(0.5-3.9) 1(ref) 0.8(0.5-1.4) 1.8(1.0-3.1) 2.8(1.3-5.8) 7.4(2.1-26.6) 
* adjusted for age, sex, city, annual income, smoking, history of cardiovascular disease, body mass index, hypertension, 
diabetes, hypercholesterolemia, and use of reninangiotensin system inhibitors. 
eGFR : glomerular filtration rate estimated with both the Modification of Diet in Renal Disease (MDRD) Study and the 
Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equations  
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Table 5. Estimated GFR decline using the MDRD study equation according to baseline characteristics and 
participant mean eGFR in the subsample with 4-year follow-up.  
  
CrudeeGFRdecline(mL/m
in/ 1.73m²/yr) 
 
Adjusted eGFR decline* 
(mL/min/1.73m²/yr) 
 N % >4 mean ± SD  mean (95% CI) P 
All 1298 17.4 1.46 ± 2.87  1.46 (1.30,1.61)  
Age (years)       
65- 70[ 303 14.5 1.16 ± 2.60  1.15 (0.83 , 1.48) 0.19 
[70-75[ 458 17.9 1.55 ± 2.87  1.56 (1.30 , 1.82)  
[75-80[ 354 19.2 1.61 ± 2.99  1.59 (1.29 , 1.89)  
≥ 80 183 17.5 1.40 ± 3.06  1.42 (1.00 , 1.84)  
Men 474 20.7 1.83 ± 2.89  1.78 (1.52 , 2.04) 0.0025 
Women 824 15.5 1.24 ± 2.84  1.27 (1.07 , 1.47)  
Diabetes†       
No 1151 15.7 1.33 ± 2.81  1.34 (1.17 , 1.50) 0.0002 
Yes 123 34.1 2.56 ± 3.23  2.45 (1.95 , 2.96)  
Unknown 24 12.5 1.86 ± 2.91  1.91 (0.77 , 3.05)  
Hypertension and BP in mm Hg    
No 288 12.8 1.23 ± 2.54  1.34 (1.00 , 1.67) 0.35 
Yes, treated       
BP < 140/90 270 19.3 1.40 ± 3.03  1.37 (1.03 , 1.71)  
140/90 ≤ BP<160/95 400 15.0 1.39 ± 2.85  1.39 (1.11 , 1.67)  
BP ≥ 160/95 340 22.6 1.78 ± 3.02  1.70 (1.39 , 2.00)  
Participant mean eGFR in mL/min/1.73 m
2
 
≥75 670 19.0 1.44 ± 2.99  1.41 (1.20 , 1.63) 0.68 
[60-75[ 430 15.3 1.39 ± 2.71  1.44 (1.17 , 1.71)  
[45-60[ 169 16.0 1.68 ± 2.76  1.70 (1.27 , 2.13)  
<45 29 20.7 1.45 ± 3.26  1.26 (0.21 , 2.31)  
 
*adjusted for age, sex, diabetes, hypertension, and participant mean eGFR over 4 years  
†Diabetes was self-reported or defined as fasting glycemia ≥ 7 mmol/L or nonfastingglycemia ≥ 11 mmol/L or antidiabetic drug use 
eGFR : glomerular filtration rate estimated with the Modification of Diet in Renal Disease (MDRD) Study equation  
BP :blood pressure  
  
  27 
Figure legends 
 
 
Figure 1 - Three-City Study flow chart 
 
Figure 2 – Prevalence of kidney damage markers according toeGFR level in the 
subsample 
Microalbuminuria defined as an albumin:creatinine ratio ≥ 3 (30) and <30 (300) mg/mmol 
(mg/g) and clinical proteinuria as a protein:creatinine ratio ≥ 50 mg/mmol (≥500 mg/g). 
Resistant hypertension defined as a blood pressure ≥ 130/80 mmHg for those with either an 
eGFR<60 mL/min/1.73 m², diabetes, proteinuria ≥ 50 mg/mmol or albuminuria ≥ 30 
mg/mmol, otherwise the threshold was 140/90 mmHg. Anemia defined as an hemoglobin <11 
g/dL 
 
Figure 3 – Prevalence of CKD stages and distribution of isolated low eGFR, 
microalbuminuria without diabetes, and at least one clinically relevant marker by CKD 
stage and sex 
Microalbuminuria defined as an albumin:creatinine ratio ≥ 3 (30) and <30 (300) mg/mmol 
(mg/g); clinically relevant markers include microalbuminuria with diabetes, clinical 
proteinuria defined as a protein:creatinine ratio ≥ 50 mg/mmol (≥500 mg/g), anaemia defined 
as an hemoglobin <11 g/dL, and resistant hypertension defined as a blood pressure ≥ 130/80 
mmHg for those with either an eGFR<60 mL/min/1.73 m², diabetes, proteinuria ≥ 50 
mg/mmol or albuminuria ≥ 30 mg/mmol, otherwise the threshold was 140/90 mmHg. 
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